Skip to main content
. 2016 Apr 29;8(2):95–103. doi: 10.5114/jcb.2016.59686

Fig. 3.

Fig. 3

Kaplan-Meier estimate of (A) biochemical no evidence of disease rate and (B) prostate cancer specific-survival rate based on prostate-specific antigen nadir (nPSA) after high-dose-rate brachytherapy combined with external beam radiation therapy, respectively. Patients were divided into 2 groups according to levels of nPSA after radiotherapy: nPSA of ≤ 0.02 ng/ml (n = 196) and nPSA of > 0.02 ng/ml (n = 20)